Toho Holdings announced an investment in AdipoSeeds, a regenerative medicine venture originating at Keio University. The companies will jointly support the development of a distribution system for drugs derived from regenerative medicine.
Toho Holdings announced that it had invested in AdipoSeeds, a startup originating at the School of Medicine of Keio University. The companies plan to jointly develop a distribution system for drugs produced through regenerative medicine, while the investment amount was not disclosed.
AdipoSeeds was established in 2016 and had capital of ¥110 million as of June 2026. The company has strengths in technology for producing platelets from adipose tissue and is researching drugs for conditions including skin ulcers. In addition to Toho Holdings, it has received funding from コージンバイオ, which will be used for expenses including the development of drug candidates.
Toho Holdings is pursuing partnerships with Teijin Regenerative Medicine and ITOCHU Corporation in the distribution of drugs produced through regenerative medicine and support for biotechnology startups. In July, it made イシンファーマ a subsidiary, a company engaged in regenerative medicine.
This investment is part of a collaboration, and has been reported as an initiative aimed at strengthening drug distribution and drug discovery support in the regenerative medicine field.